LARGO, Fla., Jan. 30 /PRNewswire-FirstCall/ -- GeoPharma, Inc. announced today that the Amended Class Action Complaint against GeoPharma relating to its announcement of FDA approval for the Company’s medical device Mucotrol(TM) was dismissed on January 27, 2006, with prejudice, by a judge in the United States District Court for the Southern District of New York and therefore the case is now closed. Plaintiffs’ earlier complaint was dismissed by the Court on September 30, 2005.
About GeoPharma
GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company’s growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma’s competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at http://www.onlineihp.com and http://www.carbslim.com .
This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries’ expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company’s management as of the date hereof, and actual results may vary based upon future events, both within and without management’s control. Important factors that could cause such differences are described in the company’s periodic filings with the Securities and Exchange Commission.
GeoPharma, Inc.
CONTACT: Dore-Falcone, VP-CFO, GeoPharma, +1-727-544-8866, ext. 244, orcdf@onlineihp.com; or investor and media relations, Rachel Levine, TheGlobal Consulting Group, +1-646-284-9439, or rlevine@hfgcg.com, forGeoPharma
